CCR2 and metabolic dysfunction-associated steatohepatitis: To date, the efficacy of agents that directly target immune cell function and recruitment is still lacking, since the dual CCR2/CCR5 inhibitor cenicriviroc did not demonstrate antifibrotic efficacy after 1 year of treatment in MASH patients with liver fibrosis in a phase III trial [176].